- Lobbying
- Lobbying by AH Capital Management, L.L.C. (d/b/a Andreessen Horowitz)
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Collin McCune | HFSC Deputy Director/Director (19-22); HRules Policy Director (18-19); HT&I Director (14-18); LC/LA/SA Rep. Shuster (13-14) HFSC Deputy Director/Director (19-22); HRules Policy Director (18-19);HT&I Director (14-18); LC/LA/SA Rep. Shuster (13-14) HFSC Deputy Director/Director (19-22); HRules Policy Director (18-19); HT&I Director (14-18); LC/LA/SA Rep.Shuster (13-14) HFSC Deputy Director/Director (19-22); HRules Policy Director (18-19);HT&I Director (14-18); LC/LA/SA Rep. Shuster (13-14) |
Colin Rom | FDA Sr.Adv.(20-21); FDA Advisor (19-20); OMB Confidential Asst. (18-19); RA/LC/SA/ Sen. Burr (14-18) FDA Sr.Adv.(20-21); FDA Advisor (19-20); OMB Confidential Asst. (18-19); RA/LA/SA/ Sen. Burr (14-18) |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
White House Office
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
White House Office
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
White House Office
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
White House Office
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
White House Office
Type of Issue
Registration
Issue(s) they said they’d lobby about: Commodity Exchange Act (CEA); Securities Act of 1933; Securities Exchange Act of 1934; Investment Company Act of 1940; Investment Advisers Act of 1940, Digital Asset legislation; Stablecoin legislation; Food, Drug and Cosmetic Act; Social Security Act; Medicare Access and CHIPS Reauthorization Act; Artificial Intelligence legislation.
Registration
Issue(s) they said they’d lobby about: Commodity Exchange Act (CEA); Securities Act of 1933; Securities Exchange Act of 1934; Investment Company Act of 1940; Investment Advisers Act of 1940; Digital Asset legislation; Stablecoin legislation.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate